RhumbLine Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.48M | Sell |
|
|||||
|
2025
Q2 | $3.02M | Buy |
|
|||||
|
2025
Q1 | $2.41M | Buy |
|
|||||
|
2024
Q4 | $2.32M | Buy |
|
|||||
|
2024
Q3 | $2.31M | Sell |
|
|||||
|
2024
Q2 | $1.97M | Buy |
|
|||||
|
2024
Q1 | $1.52M | Buy |
|
|||||
|
2023
Q4 | $1.76M | Sell |
|
|||||
|
2023
Q3 | $2.09M | Sell |
|
|||||
|
2023
Q2 | $2.21M | Buy |
|
|||||
|
2023
Q1 | $2.59M | Buy |
|
|||||
|
2022
Q4 | $3.54M | Buy |
|
|||||
|
2022
Q3 | $3.77M | Buy |
|
|||||
|
2022
Q2 | $2.95M | Sell |
|
|||||
|
2022
Q1 | $4.72M | Sell |
|
|||||
|
2021
Q4 | $4.34M | Buy |
|
|||||
|
2021
Q3 | $4.47M | Buy |
|
|||||
|
2021
Q2 | $4.79M | Buy |
|
|||||
|
2021
Q1 | $2.71M | Sell |
|
|||||
|
2020
Q4 | $2.22M | Buy |
|
|||||
|
2020
Q3 | $912K | Sell |
|
|||||
|
2020
Q2 | $1.32M | Buy |
|
|||||
|
2020
Q1 | $377K | Buy |
|
|||||
|
2019
Q4 | $635K | Buy |
|
|||||
|
2019
Q3 | $502K | Buy |
|
|||||
|
2019
Q2 | $612K | Buy |
|
|||||
|
2019
Q1 | $1.22M | Sell |
|
|||||
|
2018
Q4 | $1.21M | Buy |
|
|||||
|
2018
Q3 | $718K | Sell |
|
|||||
|
2018
Q2 | $544K | Buy |
|
|||||
|
2018
Q1 | $438K | Buy |
|
|||||
|
2017
Q4 | $402K | Sell |
|
|||||
|
2017
Q3 | $500K | Buy |
|
|||||
|
2017
Q2 | $524K | Buy |
|
|||||
|
2017
Q1 | $735K | Buy |
|
|||||
|
2016
Q4 | $536K | Buy |
|
|||||
|
2016
Q3 | $359K | Sell |
|
|||||
|
2016
Q2 | $285K | Buy |
|
|||||
|
2016
Q1 | $244K | Buy |
|
|||||
|
2015
Q4 | $855K | Buy |
|
|||||
|
2015
Q3 | $839K | Sell |
|
|||||
|
2015
Q2 | $1.14M | Sell |
|
|||||
|
2015
Q1 | $696K | Buy |
|
|||||
|
2014
Q4 | $840K | Buy |
|
|||||
|
2014
Q3 | $627K | Sell |
|
|||||
|
2014
Q2 | $848K | Buy |
|